Articles from Exact Sciences Corp.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively1. The complete findings of the study, which primarily included patients with stage III colon cancer, will be published in a peer-reviewed scientific journal on January 25.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation’s #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes common barriers of invasive screenings—like preparation and inconvenience—by allowing samples to be collected privately at home, with no special prep needed.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas.

Exact Sciences, a leading provider of cancer screening and diagnostic tests, is proud to announce a new partnership with award-winning Hispanic actor, TV personality and philanthropist Carlos Ponce, as part of its efforts to increase awareness of colorectal cancer – also known as colon cancer – and the importance of screening within the Hispanic community. The company recently launched a Spanish-language advertising campaign.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening may reduce the incidence of stage IV cancer and, subsequently, cancer mortality over 10 years. Another new analysis from the DETECT-A study suggests that adding MCED testing complements guideline-recommended lung cancer screening without affecting adherence to current standard of care. These findings will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG takes place October 25-30, 2024, in Philadelphia, Pennsylvania. Exact Sciences will also present new data on improving adherence to help close the gap in CRC screening. ACG abstracts are available on the meeting website.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved the Cologuard Plus™ test, the company’s next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation titled, “Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort.”

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the first patient has joined its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence (RWE) study at Baylor Scott & White, the primary study site and largest not-for-profit health system in Texas. The multi-site study will enroll up to 25,000 patients, evaluating the clinical performance, patient and provider experience, and psychological impact of MCED testing over a five-year period. Endeavor Health, a Chicago-area health system serving more than 1.4 million patients, will start enrolling patients this fall. The U.S. Food and Drug Administration (FDA) recently authorized an investigational device exemption (IDE) for the Exact Sciences MCED test, allowing its use in the Falcon Registry. This study will provide valuable insight to further inform the development and commercialization of the company’s future MCED test and support discussions with regulatory agencies, payers, and guideline bodies.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared new modeling data today describing the projected impact of the Cologuard test on patients, health care professionals, and the U.S. health care system since its FDA approval 10 years ago.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $699 million for the second quarter ended June 30, 2024, compared to $622 million for the same period of 2023.

Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded a total of $1.5 million to 28 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making health care more accessible, with a focus on medically underserved populations.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® test in racially and ethnically diverse patients. Exact Sciences will also present data on its approach to multi-cancer early detection (MCED) across multiple tumor types, plus additional real-world evidence showing optimized screening adherence strategies for the Cologuard® test as well as high adherence rates for repeat screenings.

Exact Sciences (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company’s work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To Work, surpassing the average U.S. company by an impressive margin of 28 points.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week® (DDW) 2024, May 18-21 in Washington, D.C. This includes data on Cologuard®, the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus™. Further details can be found at ddw.org.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.

Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a new series of 1.75% Convertible Senior Notes due 2031 (the “New Notes”) in exchange for (i) the retirement of $359.7 million aggregate principal amount of the holders’ Existing Notes, and (ii) payment to the Company of approximately $266.8 million in cash. The closing of the transaction is expected to occur on April 17, 2024, subject to customary closing conditions.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening. ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population. These data will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2024, April 5-10 in San Diego, California.1

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Exact Sciences (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients. The initiative expands the collection of data accessible to Mayo Clinic researchers and clinicians to advance cancer research and patient care.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE).1,2 Findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and Hepatology journal.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world.

Exact Sciences Corp. (NASDAQEXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society recommendations.2

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva sample for 10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.